Back to top
more

Rapt Therapeutics (RAPT)

(Delayed Data from NSDQ)

$9.99 USD

9.99
21,272

-0.11 (-1.09%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $9.94 -0.05 (-0.50%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -21.47% and 83.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 12.50% and 31.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.67% and 71.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -107.14% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -5.00% and -33.38%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rapt Therapeutics (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Rapt Therapeutics (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

RAPT THERAPTICS (RAPT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -1.61% and -39.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

RAPT THERAPTICS (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

RAPT Reports Positive Data From Atopic Dermatitis Study

by Zacks Equity Research

RAPT up on positive data from an early-stage study in patients with moderate-to-severe atopic dermatitis.

Zacks Equity Research

RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next?

by Zacks Equity Research

RAPT Therapeutics (RAPT) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Zacks Equity Research

Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.

Zacks Equity Research

RAPT THERAPTICS (RAPT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of -26.92% and -28.12%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RAPT THERAPTICS (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

RAPT THERAPTICS (RAPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Do Options Traders Know Something About RAPT Therapeutics (RAPT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to RAPT Therapeutics (RAPT) stock based on the movements in the options market lately.

Zacks Equity Research

RAPT THERAPTICS (RAPT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

RAPT THERAPTICS (RAPT) delivered earnings and revenue surprises of 3.70% and -36.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1%

by Zacks Equity Research

RAPT Therapeutics (RAPT) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

RAPT's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in RAPT Therapeutics.